FibroBiologics (NASDAQ:FBLG) Earns “Buy” Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $16.00 price target on the stock.

A number of other research analysts have also recently commented on the company. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of FibroBiologics in a research note on Thursday, February 13th. Rodman & Renshaw began coverage on FibroBiologics in a report on Thursday, December 12th. They set a “buy” rating and a $12.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, FibroBiologics has an average rating of “Buy” and an average price target of $13.00.

FibroBiologics Stock Performance

Shares of FBLG stock opened at $1.26 on Thursday. The firm’s 50 day moving average price is $1.72 and its 200-day moving average price is $2.27. FibroBiologics has a one year low of $0.98 and a one year high of $14.70.

Hedge Funds Weigh In On FibroBiologics

Several hedge funds and other institutional investors have recently made changes to their positions in FBLG. The Manufacturers Life Insurance Company purchased a new stake in shares of FibroBiologics during the third quarter worth approximately $32,000. Jane Street Group LLC purchased a new stake in shares of FibroBiologics in the 3rd quarter valued at approximately $37,000. Intech Investment Management LLC acquired a new stake in shares of FibroBiologics in the 4th quarter valued at $25,000. Virtu Financial LLC purchased a new stake in shares of FibroBiologics during the 4th quarter worth $30,000. Finally, Raymond James Financial Inc. acquired a new position in shares of FibroBiologics during the fourth quarter worth $37,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.